ArticleOncotarget2017

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Simon Baldacci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.